557 related articles for article (PubMed ID: 10177950)
21. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
[TBL] [Abstract][Full Text] [Related]
22. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
23. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
24. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
[TBL] [Abstract][Full Text] [Related]
25. Teva v. Eisai: what's the real "controversy"?
Wang GL
Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
[TBL] [Abstract][Full Text] [Related]
26. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
[TBL] [Abstract][Full Text] [Related]
27. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
[TBL] [Abstract][Full Text] [Related]
28. FDA's role in making exclusivity determinations.
Dickinson EH
Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
[No Abstract] [Full Text] [Related]
29. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
30. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
31. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
32. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
Panattoni LE
J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
[TBL] [Abstract][Full Text] [Related]
33. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
34. Fifty years of drug amendments revisited: in easy-to-swallow capsule form.
Kaplan AH
Food Drug Law J; 1995; 50 Spec():179-96. PubMed ID: 10343042
[No Abstract] [Full Text] [Related]
35. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
36. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
[No Abstract] [Full Text] [Related]
37. GATT implementation and generic drug approval.
Safir PO; Lassman SM
Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
[No Abstract] [Full Text] [Related]
38. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
39. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
Kraushaar KJ
Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
[No Abstract] [Full Text] [Related]
40. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
Zain S
Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
